Home Blog

0 12

Patent Number: 9,040,770

Grant date: December 31, 1969
Priority date: August 11, 2003
Estimated expiration date: August 11, 2023
Inventor(s): Klimanskaya; Irina (Upton, MA), Lanza; Robert (Clinton, MA)
Assignee(s): Ocata Therapeutics, Inc. (Marlborough, MA)
External link: USPTO website

Abstract:

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

0 10

Patent Number: 9,040,694

Grant date: December 31, 1969
Priority date: August 11, 2003
Estimated expiration date: August 11, 2023
Inventor(s): Hong; Charles C. (Nolensville, TN), Hopkins; Corey R. (Nolensville, TN), Hatzopoulos; Antonis K. (Nashville, TN), Lindsley; Craig W. (Brentwood, TN), Hao; Jijun (Nashville, TN)
Assignee(s): Vanderbilt University (Nashville, TN)
External link: USPTO website

Abstract:

The presently-disclosed subject matter relates to compounds of the formula: ##STR00001## and methods for use thereof. The presently-disclosed subject matter relates methods of selectively differentiating a stem cell, and methods of screening for compounds useful for enhancing terminal differentiation of committed cardiac progenitor cells.

0 10

Patent Number: 9,040,676

Grant date: December 31, 1969
Priority date: August 11, 2003
Estimated expiration date: August 11, 2023
Inventor(s): Phillips; M. Ian (Tampa, FL), Tang; Yao Liang (St. Petersburg, FL)
Assignee(s): UNIVERSITY OF SOUTH FLORIDA (Tampa, FL)
External link: USPTO website

Abstract:

The invention concerns a system for modulating tissue physiology, for example, to prevent or reverse tissue damage caused by disease. The system utilizes vigilant cells that include stable vectors containing a gene switch/biosensor and a gene amplification system. The vectors allow expression of a transgene (such as a cardioprotective gene) in the vigilant cells to be regulated in response to a physiological signal, to be switched on or off, and to provide sufficient levels of the transgene product to achieve a desired result, e.g., prevention or reversal of myocardial cell damage. In addition to myocardial infarction, the vectors can be used to treat cells in a number of other disease states, including diabetes, cancer, stroke, and atherosclerosis. These approaches to stem cell-based gene therapy provide a novel strategy not only for treatment but for prevention of cell destruction.

0 10

Patent Number: 9,040,300

Grant date: December 31, 1969
Priority date: January 23, 2004
Estimated expiration date: January 23, 2024
Inventor(s): Kobayashi; Eiji (Tokushima, JP), Wada; Tamaki (Tokushima, JP), Doi; Masako (Tokushima, JP)
Assignee(s): OTSUKA PHARMACEUTICAL FACTORY, INC. (Tokushima, JP)
External link: USPTO website

Abstract:

Methods of washing adherent cells, capable of effectively suppressing cell death due to proteolytic enzyme treatment for detaching the adherent cell from a culture vessel and subsequent cell treatment; cell-washing solutions used for the washing method; methods of producing cell suspensions for transplantation using the cell-washing solution; and kits comprising the cell-washing solution. Trehalose or its derivative or a salt thereof is added to physiological aqueous solutions to prepare cell-washing solutions containing trehalose or its derivative or a salt thereof as an active ingredient. The cell-washing solutions can be used to wash adherent cells before detaching the adherent cells from a culture vessel by proteolytic enzyme treatment to suppress cell death due to the proteolytic enzyme treatment. The concentration of trehalose applied to the cell-washing solution may be a concentration capable of suppressing the cell death due to the proteolytic enzyme treatment, such as 0.1 to 20 (w/v) %.

0 11

Patent Number: 9,040,299

Grant date: December 31, 1969
Priority date: January 23, 2004
Estimated expiration date: January 23, 2024
Inventor(s): Phan; Toan-Thang (Singapore, SG)
Assignee(s): CELLRESEARCH CORPORATION PTE LTD (Singapore, SG)
External link: USPTO website

Abstract:

The present invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells.

0 5

Patent Number: 9,040,298

Grant date: December 31, 1969
Priority date: January 23, 2004
Estimated expiration date: January 23, 2024
Inventor(s): Yang; Yoon-Sun (Seoul, KR), Oh; Won Il (Seoul, KR), Jeon; Hong Bae (Seoul, KR), Jung; Mee Hyun (Seoul, KR), Jeong; Sang Young (Seoul, KR)
Assignee(s): Medipost Co., Ltd. (Seoul, KR)
External link: USPTO website

Abstract:

Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.

0 4

Patent Number: 9,040,297

Grant date: December 31, 1969
Priority date: January 23, 2004
Estimated expiration date: January 23, 2024
Inventor(s): Amit; Michal (Misgav, IL), Itskovitz-Eldor; Joseph (Haifa, IL)
Assignee(s): Technion Research & Development Foundation Limited (Haifa, IL)
External link: USPTO website

Abstract:

A method of expanding and maintaining human embryonic stem cells (ESCs) in an undifferentiated state by culturing the ESCs in a suspension culture under culturing conditions devoid of substrate adherence is provided. Also provided are a method of deriving ESC lines in the suspension culture and methods of generating lineage-specific cells from ESCs which were expanded in the suspension culture of the present invention.

0 5

Patent Number: 9,040,296

Grant date: December 31, 1969
Priority date: January 23, 2004
Estimated expiration date: January 23, 2024
Inventor(s): Mehtali; Majid (Coueron, FR), Champion-Arnaud; Patrick (Nantes, FR), Leon; Arnaud (Nantes, FR)
Assignee(s): Valneva (Lyon, FR)
External link: USPTO website

Abstract:

The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx.RTM. cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.

0 4

Patent Number: 9,040,097

Grant date: December 31, 1969
Priority date: January 23, 2004
Estimated expiration date: January 23, 2024
Inventor(s): Claiborne; Eva (San Rafael, CA), Ellis; Jennifer Clara (Lawton, OK)
Assignee(s): Indermica, Inc. (Mill Valley, CA)
External link: USPTO website

Abstract:

Compositions for reducing the appearance of wrinkles, reducing the effects of aging and/or improving the appearance of skin. The composition may include at least one fluorinated perfluorocarbon; stem cells from at least one plant species; and at least one peptide complex that reduces release of acetylcholine. Other embodied compositions include at least one collagen stimulating peptide; at least one anti-inflammatory compound; and at least one skin tightening agent.

0 5

Patent Number: 9,040,092

Grant date: December 31, 1969
Priority date: January 23, 2004
Estimated expiration date: January 23, 2024
Inventor(s): Edelman; Elazer R. (Brookline, MA), Nugent; Helen Marie (Needham, MA), Methe; Heiko (Boston, MA)
Assignee(s): Massachusetts Institute of Technology (Cambridge, MA)
External link: USPTO website

Abstract:

Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity.